Servier's Protelos and Osseor are still important despite VTE and skin concerns, says EMA
This article was originally published in Scrip
Servier's bone drugs, Protelos and Osseor (strontium ranelate) is still an "important treatment" for women with osteoporosis, says the European Medicines Agency. The drugs' benefit: risk profile remains favourable, but the medicine is no longer to be recommended for certain patients, while warnings on serious skin reaction are to be updated.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.